# OnCo record nct07016399 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07016399/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07016399", "NCT07016399" ;
  schema:name "Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC"@en ;
  schema:description "A phase 2 trial of carboplatin, cyclophosphamide, darolutamide, doxorubicin and other drugs in triple-negative breast cancer, run by Vandana Abramson, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07016399/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07016399> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/> .